Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

To be considered for the POSEIDON study, patients generally need to be 18 years or older and have non-small cell lung cancer that has spread. An important requirement is that your cancer cells must not have certain specific gene changes, known as EGFR mutations or ALK fusions, as the study is focusing on cancers without these particular features. You also shouldn't have had any chemotherapy or other standard drug treatments for your advanced lung cancer yet.

There are also some health requirements. Your general health and ability to carry out daily activities, often described as your 'performance status,' should be good (rated 0 or 1). You also shouldn't have previously received certain types of immune-boosting treatments, except for some cancer vaccines.

However, some conditions would mean you can't join the study. For example, if you have certain types of autoimmune diseases (where your immune system attacks your own body), or if you have specific active infections like tuberculosis, hepatitis B, hepatitis C, or HIV. Having brain spots (metastases) or spinal cord compression would also exclude you, unless they are stable and you are no longer taking steroid medication for them.

If you decide to take part in the POSEIDON study, you would be randomly assigned to one of three treatment groups, much like drawing straws, so neither you nor your doctor chooses which group you're in. All groups involve receiving treatment in cycles. You'll have regular hospital visits for your treatments and check-ups. During these visits, the medical team will monitor your health closely, perform physical exams, and take blood tests.

You'll also have scans, like CT scans, at regular intervals to see how your cancer is responding to the treatment. These scans will continue until the treatment is no longer working as well as hoped. Even after you stop the main study treatment, the research team will continue to follow up with you to check on your overall health and well-being for the duration of the study.

The total duration of your participation will vary. The treatment phase, including regular assessments, continues as long as the treatment is beneficial and you are tolerating it. After treatment, you will be followed for survival until the study ends, which could be several years.